BridgeBio Pharma
BBIO
61 hedge funds and large institutions have $2.7B invested in BridgeBio Pharma in 2019 Q2 according to their latest regulatory filings, with 61 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
86.89% more ownership
Funds ownership: 0% → 86.89% (+87%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
+$1.01B |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$726M |
| 3 |
AIG
American International Group
New York
|
+$184M |
| 4 |
PA
Perceptive Advisors
New York
|
+$183M |
| 5 |
ACM
Aisling Capital Management
New York
|
+$105M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Federated Hermes
Pittsburgh,
Pennsylvania
| $135K | +$136K | +5,000 | New |
|
|
TAM
52
Tiverton Asset Management
Wilimington,
Delaware
| $76K | +$76.3K | +2,800 | New |
|
|
GHCM
53
Glen Harbor Capital Management
San Diego,
California
| $20K | +$20.4K | +748 | New |
|
|
MCIM
54
Meadow Creek Investment Management
Atlanta,
Georgia
| $17K | +$16.8K | +616 | New |
|
55
UBS Group
Zurich,
Switzerland
| $16K | +$16.4K | +600 | New |
|
|
EP
56
Elkfork Partners
Portland,
Oregon
| $13K | +$13.2K | +484 | New |
|
|
AAMU
57
Amundi Asset Management US
Boston,
Massachusetts
| $13K | +$13.6K | +500 | New |
|
|
TAM
58
Tyers Asset Management
Austin,
Texas
| $10K | +$9.6K | +352 | New |
|
|
CCA
59
Catalyst Capital Advisors
Huntington,
New York
| $8K | +$7.77K | +285 | New |
|
|
FIA
60
FNY Investment Advisers
New York
| $6K | +$6.98K | +256 | New |
|
61
Legal & General Group
London,
United Kingdom
| $2K | +$1.53K | +56 | New |
|
BBIO Hedge Fund Activity: Q2 2019 in Review
61 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2019, worth a combined $2.7B.
Buyers outnumbered sellers: 61 funds opened new BBIO positions and 0 closed out — a net gain of 61 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kohlberg Kravis Roberts & Co, opening a new position worth an estimated $1.01B.
- 61 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $2.7B of BridgeBio Pharma stock for Q2 2019.
- 61 funds opened new BridgeBio Pharma positions in Q2 2019 and 0 closed out, a net change of +61 holders.
- The largest BridgeBio Pharma buyer in Q2 2019 was Kohlberg Kravis Roberts & Co, an estimated $1.01B added.
Based on aggregated 13F filings for Q2 2019.